Medtech Manufacturing for Innovators & Start Ups: What You Most Need to Know

Insights from a deep dive into medical device innovation and production with GCMI’s Saylan Lukas and GaMEP’s Dean Hettenbach

Given the patient safety requirements codified in the United States Code of Federal Regulations overseen and enforced by the Food and Drug Administration, medical device innovation is a challenging enterprise to say the least.

 

It is also a landscape filled with pitfalls that need a holistic, long range view to avoid them. Considering what manufacturing at scale means for a new device or technology is one such pitfall that needs consideration earlier in the design and development process than one might know or believe.

 

Design decisions with manufacturing at the right scale need to be made upfront, even if large-scale production seems far off. A device might serve its purpose perfectly as a 3D printed prototype, but producing it at scale for clinical use based on designs only appropriate for small batch production can become an expensive nightmare.

 

Last month, GCMI Interim Executive Director Saylan Luke and Georgia Manufacturing Extension Partnership’s Dean Hettenbauch unpacked the common challenges that many face when entering the medical device space and the steps to take to avoid common pitfalls [particularly as it relates to manufacturing].

 

While we invite you to check out the hour long recording full of high value information and insights, but as long as you’re here, check out some of the top takeaways.

 

Engage regulators early, but be well prepared.

Start the process of engaging the FDA (assuming you intend to market your device in the United States) as soon as possible. They are there to help and more well equipped and committed than ever to do so. BUT, put in the time prior to any engagement with regulators to be as well informed as possible. Know that they don’t answer vague questions. Seriously consider, vet and engage a regulatory consultant with experience specific to your technology and its prospective pathway or pathways.



CLICK HERE TO KEEP READING
September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS